Nevro (NYSE:NVRO) Issues Earnings Results, Beats Expectations By $0.32 EPS

Nevro (NYSE:NVRO) posted its quarterly earnings results on Tuesday. The medical equipment provider reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.02) by $0.32, Briefing.com reports. Nevro had a negative net margin of 21.69% and a negative return on equity of 30.22%. The business had revenue of $101.90 million during the quarter, compared to the consensus estimate of $97.90 million. During the same quarter last year, the firm posted ($0.98) EPS. Nevro’s revenue was up 5.8% compared to the same quarter last year.

Nevro Price Performance

Shares of NVRO traded down $1.18 during midday trading on Wednesday, reaching $10.35. The stock had a trading volume of 334,945 shares, compared to its average volume of 496,352. The company has a market capitalization of $379.64 million, a price-to-earnings ratio of -4.04 and a beta of 0.96. The company has a current ratio of 6.37, a quick ratio of 4.94 and a debt-to-equity ratio of 0.72. Nevro has a 12-month low of $10.14 and a 12-month high of $28.89. The company’s 50-day moving average is $13.21 and its 200 day moving average is $16.27.

Wall Street Analysts Forecast Growth

NVRO has been the subject of several research reports. Robert W. Baird reduced their price target on shares of Nevro from $23.00 to $19.00 and set a “neutral” rating for the company in a research report on Thursday, February 22nd. Mizuho lowered their target price on Nevro from $20.00 to $16.00 and set a “neutral” rating on the stock in a research note on Thursday, April 11th. Citigroup cut their price target on Nevro from $18.00 to $16.00 and set a “neutral” rating for the company in a research note on Wednesday, April 3rd. StockNews.com raised shares of Nevro from a “sell” rating to a “hold” rating in a report on Friday, March 1st. Finally, Royal Bank of Canada decreased their price target on Nevro from $18.00 to $16.00 and set a “sector perform” rating on the stock in a research report on Monday, April 15th. One analyst has rated the stock with a sell rating, twelve have issued a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $20.00.

About Nevro

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.